| Product Name | Indirubin-3′-monoxime |
| Description |
GSK, CDK kinase inhibitor |
| Purity | >98% (HPLC) |
| CAS No. | 160807-49-8 |
| Molecular Formula | C16H11N3O2 |
| Molecular Weight | 277.3 |
| Field of Use | Not for use in humans. Not for use in diagnostics or therapeutics. For in vitro research use only. |
| Storage Temperature | -20ºC |
| Shipping Temperature | Shipped Ambient |
| Product Type | Inhibitor |
| Solubility | Soluble to 100 mM in DMSO and to 100 mM in ethanol |
| Source | Synthetic |
| Appearance | Red solid |
| SMILES | O=C/2/N=C1/C=CC=C/C1=C2c4c(NO)c3ccccc3n4 |
| InChI | InChI=1S/C16H11N3O2/c20-16-13(9-5-1-3-7-11(9)18-16)15-14(19-21)10-6-2-4-8-12(10)17-15/h1-8,17,19,21H |
| InChIKey | LDEWQRSYYHTQRA-UHFFFAOYSA-N |
| Safety Phrases |
Classification: Not a hazardous substance or mixture. Safety Phrases: S22 - Do not breathe dust. S24/25 - Avoid contact with skin and eyes. S36/37/39 - Wear suitable protective clothing, gloves and eye/face protection. |
| Cite This Product | Indirubin-3'-monoxime (StressMarq Biosciences Inc., Victoria BC CANADA, Catalog # SIH-502) |
| Alternative Names | Indirubin-3'-monoxime, 3-[1,3-Dihydro-3-(hydroxyimino)-2H-indol-2-ylidene]-1,3-dihydro-2H-indol-2-one, Indirubin-3′-oxime |
| Research Areas | Apoptosis, Cancer, Cancer Growth Inhibitors, Cell Signaling, Tyrosine Kinase Inhibitors |
| PubChem ID | 5326739 |
| Scientific Background | Indirubin-3'-monoxime is a potent inhibitor of cyclin-dependent kinases (CDKs) and glycogen synthase kinase-3β (GSK-3β), both of which are implicated in neurodegenerative diseases. By modulating GSK-3β activity, it may influence tau phosphorylation and neuronal survival, making it a candidate for Alzheimer’s and Parkinson’s disease research. Its ability to regulate cell cycle and kinase signaling pathways also supports its use in studies of neuroprotection and neural regeneration. |
| References | 1. Damiens E., Baratte B., Marie D., Eisenbrand G., & Meijer L. (2001) Oncogene. 20(29): 3786–3797. |
Reviews
There are no reviews yet.